These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33184106)

  • 1. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of
    Williams MM; Spoelstra NS; Arnesen S; O'Neill KI; Christenson JL; Reese J; Torkko KC; Goodspeed A; Rosas E; Hanamura T; Sams SB; Li Z; Oesterreich S; Riggins RB; Jacobsen BM; Elias A; Gertz J; Richer JK
    Cancer Res; 2021 Feb; 81(3):732-746. PubMed ID: 33184106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
    Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
    JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
    Liang J; Ingalla ER; Yao X; Wang BE; Tai L; Giltnane J; Liang Y; Daemen A; Moore HM; Aimi J; Chang CW; Gates MR; Eng-Wong J; Tam L; Bacarro N; Roose-Girma M; Bellet M; Hafner M; Metcalfe C
    Sci Transl Med; 2022 Sep; 14(663):eabo5959. PubMed ID: 36130016
    [No Abstract]   [Full Text] [Related]  

  • 8. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
    Kingston B; Pearson A; Herrera-Abreu MT; Sim LX; Cutts RJ; Shah H; Moretti L; Kilburn LS; Johnson H; Macpherson IR; Ring A; Bliss JM; Hou Y; Toy W; Katzenellenbogen JA; Chandarlapaty S; Turner NC
    Cancer Discov; 2024 Feb; 14(2):274-289. PubMed ID: 37982575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
    J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
    Udden SN; Wang Q; Kumar S; Malladi VS; Wu SY; Wei S; Posner BA; Geboers S; Williams NS; Liu Y; Sharma JK; Mani RS; Malladi S; Parra K; Hofstad M; Raj GV; Larios JM; Jagsi R; Wicha MS; Park BH; Gupta GP; Chinnaiyan AM; Chiang CM; Alluri PG
    JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35881485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal modulation of ESR1 mutant metastasis.
    Gu G; Tian L; Herzog SK; Rechoum Y; Gelsomino L; Gao M; Du L; Kim JA; Dustin D; Lo HC; Beyer AR; Edwards DG; Gonzalez T; Tsimelzon A; Huang HJ; Fernandez NM; Grimm SL; Hilsenbeck SG; Liu D; Xu J; Alaniz A; Li S; Mills GB; Janku F; Kittler R; Zhang XH; Coarfa C; Foulds CE; Symmans WF; Andò S; Fuqua SAW
    Oncogene; 2021 Feb; 40(5):997-1011. PubMed ID: 33323970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects.
    Arnesen S; Blanchard Z; Williams MM; Berrett KC; Li Z; Oesterreich S; Richer JK; Gertz J
    Cancer Res; 2021 Feb; 81(3):539-551. PubMed ID: 33184109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Blockade of Activating
    Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of ESR1 variants in breast cancer.
    Heeke AL; Elliott A; Feldman R; O'Connor HF; Pohlmann PR; Lynce F; Swain SM; Nunes MR; Magee D; Oberley MJ; Swenson J; Vidal G; Isaacs C; Schwartzberg L; Korn WM; Tan AR
    Breast Cancer Res Treat; 2022 Nov; 196(2):279-289. PubMed ID: 36125660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
    Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
    Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha-Mutant Endometrial Cancer.
    Blanchard Z; Rush CM; Arnesen S; Vahrenkamp JM; Rodriguez AC; Jarboe EA; Brown C; Chang MEK; Flory MR; Mohammed H; Modzelewska K; Lum DH; Gertz J
    Mol Cancer Res; 2023 Oct; 21(10):1023-1036. PubMed ID: 37363949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.